« Back to Record
Citation APA

Almhanna, K., Bendell, J., Bols, A., Feliu, J., Starling, N., Enzinger, P., Mahalingham, D., Messersmith, W., Yang, H., Fasanmade, A. A., Danaee, H., Wright, D., Kalebic, T., Mercade, T. M., Van Laethem, J.-L., Gracian, A. C., Guillen-Ponce, C., Faris, J., López, C. M., & Hubner, R. R. (2017). A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Investigational new drugs, 35(5), 634-641. doi:10.1007/s10637-017-0473-9


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/260744

Almhanna, K., Bendell, J., Bols, A., Feliu, J., Starling, N., Enzinger, P., Mahalingham, D., Messersmith, W., Yang, H., Fasanmade, A. A., Danaee, H., Wright, D., Kalebic, T., Mercade, T. M., Van Laethem, J.-L., Gracian, A. C., Guillen-Ponce, C., Faris, J., López, C. M., & Hubner, R. R. (2017). A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Investigational new drugs, 35(5), 634-641. doi:10.1007/s10637-017-0473-9